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GENE EXPRESSION IN NEUROLOGICAL DISEASE: 
 
AUTISM AND PARKINSON’S DISEASE 
 
AFRAA AWAD ALSAMKARI 
 
 
ABSTRACT 
 Parkinson’s disease (PD) and autism are prevalent diseases in two disparate age 
groups. The neuropathology underlying these diseases involves the major 
neurotransmitters, dopamine and GABA, and/ or their receptors. The current study 
investigated mRNA gene expressions of the GAD67 in autistic striatum and the DRD1 in 
the Parkinsonian dorsolateral prefrontal cortex.  In situ hybridization histochemistry for 
GAD67 mRNA levels in post-mortem striatal specimens from autistic individuals was 
compared to those of normal controls. Similarly, a nonradioactive in situ hybridization 
newly emerging method, RNAscope®, was used to assess the D1 receptor mRNA gene 
expression in post-mortem specimens of the dorsolateral prefrontal cortex of PD and 
control brains.  The GAD67 mRNA labeling intensity that was measured on X-ray films 
and on emulsion radioautograph sections did not vary significantly between the autistic 
samples and the normal control samples. On the other hand, DRD1 mRNA levels showed 
a significant increase in the Parkinsonian dorsolateral prefrontal cortex specimens as 
compared to their normal counterparts. The GAD65 mRNA labeling results corresponded 
with the GAD67 mRNA levels. The similar GAD67 and GAD65 mRNA patterns in the 
autism group and the control group may suggest that the hyper-excitability hypothesis 
can be accounted for by an increase in the glutamatergic activity rather than a decrease in 
the GABAergic system. The increase in the DRD1 mRNA in the Parkinson’s disease 
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dorsolateral prefrontal cortex may be interpreted in light of the expected upregulation of 
the D1 receptor in cases of dopamine depletion as the treatment-status was unknown. In 
conclusion, research investigating the neurotransmitters’ gene expression in Parkinson’s 
disease and in autism spectrum disorder needs more neurobiological studies in order to 
establish some knowledge regarding the temporality, and the genetic profile mapping of 
the diseases. Likewise, more research is encouraged to relate the symptoms and behaviors 
associated with disease to their anatomical origins. 
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1. INTRODUCTION 
 
1.1. The Basal Ganglia Anatomy 
 The basal ganglia (BG) are a group of subcortical nuclei that develop from the 
primitive telencephalic vesicle (Ring, 2002). Classically, the major components of the 
basal ganglia are: the neostriatum, pallidum, subthalamic nucleus, and substantia nigra 
(Tepper, Abercrombie, & Bolam, 2007). The neostriatum is comprised of the caudate 
nucleus and the putamen. The pallidum is a term used to describe the globus pallidus 
including its two functionally distinct segments: the globus pallidus internus (GPi) and 
the globus pallidus externus (GPe) (Tepper et al., 2007). The subtantia nigra has also two 
parts: the substantia nigra pars reticulata (SNpr) and the substantia nigra pars compacta 
(SNpc). The subthalamic nucleus is a homogeneous nucleus in the mesencephalon 
(Tepper et al., 2007). The neurons in the neostriatum, the pallidum, and the substantia 
nigra pars reticulata are mainly GABAergic neurons (Tepper et al., 2007). However, the 
substantia nigra pars compacta has dopaminergic neurons whereas the subthalamic 
nucleus is mainly occupied by glutamatergic neurons (Tepper et al., 2007). The 
neostriatum, the pallidum, the subthalamic nucleus, and the substantia nigra are critical 
structures for the initiation and coordination of voluntary movements. This constellation 
of nuclei is referred to as the dorsal division of the basal ganglia and it serves motor and 
associative functions (Tepper et al., 2007). On the other hand, the ventral division of the 
basal ganglia serves other behavioral functions, and it is less strictly defined and 
delineated. The ventral division is composed of the nucleus accumbens, the ventral 
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pallidum, and the medial aspects of the subthalamic nucleus and substantia nigra (Tepper 
et al., 2007). Nucleus accumbens is part of the striatum because it shares similar 
histological, neurochemical, and connectional characteristics with the caudate and 
putamen (Groenewegen, 2003). In addition, it is known as the ventral striatum, and it is 
considered functionally a component of the limbic system (Ring, 2002). Based on these 
differing components of the basal ganglia, the functions of the basal ganglia can be 
viewed as motor and non-motor functions, i.e.: emotional, cognitive and behavioral 
functions (Ring, 2002). The basal ganglia nuclei serve as pivotal points for many 
neuronal connections. For example, the flow of the information from the cortex, the 
corticostriatal input, can be transmitted to the output nuclei through the caudate either 
directly or indirectly (Haber, 2014). As the name implies, the direct pathway transmits 
the corticostriatal information directly to globus pallidus internus (GPi) and the substantia 
nigra pars reticulata (SNpr) (Groenewegen, 2003). The globus pallidus internus and the 
substantia nigra pars reticulata are the output neurons of the basal ganglia as they project 
to the thalamic nuclei, which send output information to the cortex (Bolam, Hanley, 
Booth, & Bevan, 2000). The indirect pathway is a much complex pathway that passes 
through the interconnections of the globus pallidus externus and the subthalamic nucleus 
(Bolam et al., 2000). (See Figure 1.)  
 The output of the basal ganglia in resting conditions is inhibitory (Bolam et al., 
2000). This inhibitory resting state is the result of the exceedingly high inhibitory tonic 
activity of the globus pallidus internus and the substantia nigra pars reticulata (SNpr) 
(Groenewegen, 2003). The corticostriatal excitation of the medium spiny neurons (MSN) 
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in the striatum will inhibit the high inhibitory tonic activity of the globus pallidus internus 
and the substantia nigra pars reticulata, and subsequently, this disinhibits the thalamo-
cortical system resulting in activation of the motor function (Bolam et al., 2000). In 
contrast to this, activation of the indirect pathway leads to the opposite physical effect, 
i.e. increased firing of output neurons and increased inhibition of basal ganglia targets 
represented by thalamic nuclei (Bolam et al., 2000). 
 While the cortex is the main excitatory input to the basal ganglia, and is organized 
in a topographic pattern, the basal ganglia through the thalamus is the main influence on 
the GABAergic interneurons in the cortex (Ramamoorthi & Lin, 2011). In addition, 
according to these topographic corticostriatal projections the basal ganglia play an 
important role in a wide array of functions that include motor-planning, movement, 
sensory-motor integration, and limbic function (Bolam et al., 2000). There are no distinct 
anatomical boundaries between these functional areas, however, they are roughly 
delineated. The sensorimotor sector of the basal ganglia is the dorsolateral striatum that 
receives convergent input from the motor, premotor cortex, and sensory cortical areas 
(Groenewegen, 2003). The associative sector is the ventromedial striatum as it receives 
input from the frontal, temporal, and parietal association cortical areas (Groenewegen, 
2003). The limbic sector involves the nucleus accumbens and the most ventral parts of 
the striatum receiving projections from amygdala, hippocampus, parahippocampal, and 
orbitofrontal cortex (Groenewegen, 2003). 
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1.2. Basal Ganglia Circuitry 
The circuitry of the basal ganglia is key to this spectrum of functions. These 
functions are disturbed in a wide array of neurological diseases that may involve the basal 
ganglia, such as: autism spectrum disorders (ASD), Parkinson’s disease, Huntington’s 
disease, and Tourette’s syndrome (Bechard, Cacodcar, King, & Lewis, 2016). The basal 
ganglia circuits are typically grouped into: (1) the sensorimotor circuit, (2) the associative 
or cognitive circuit, and (3) the limbic circuit. These circuits innervate the motor and pre-
motor cortices; the dorsolateral prefrontal cortex; and the lateral orbitofrontal and anterior 
cingulate cortex, respectively (Langen, Durston, Kas, van Engeland, & Staal, 2011). 
 The principal function of corticostriatal circuits is to control and select goal-
directed motor, cognitive, and motivational behavior. Disruption of coordinated function 
within the basal ganglia, or between striatal and forebrain structures results in changes in 
behavior often including repetitive or stereotyped behavior (Langen et al., 2011). 
Repetitive motor behaviors are purposeless unyielding patterns that serve no function 
(Bechard et al., 2016). The underlying mechanism of repetitive behavior is believed to 
involve an imbalance between the direct pathway and the indirect pathway as the direct 
pathway neurons facilitate selection of relevant motor programs, whereas, the indirect 
pathway suppresses competing motor programs (Bechard et al., 2016). In the direct 
pathway, striatum through its striatal projection neurons send GABAergic inhibitory 
signals to the output neurons in the globus pallidus internus and the substantia nigra pars 
reticulata. Inhibiting the globus pallidus internus and the substantia nigra pars reticulata 
releases the ventroanterior and ventrolateral nuclei of the thalamus to excite the premotor 
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and motor areas of the cortex, which in turn, facilitates motor activity. On the other hand, 
in the indirect pathway, the striatum inhibits the globus pallidus externus, and 
subsequently, releases the subthalamic nucleus, which activates the globus pallidus 
internus. Thus, the thalamic nuclei become suppressed and movement is ceased. 
Interestingly, dopamine has contradictory effects on the two pathways through the two 
different receptors on the MSNs of the striatum. Indeed, the direct pathway and the 
indirect pathway are modulated through two different populations of MSNs. The direct 
pathway is enabled by the Dynorphin-D1-expressing MSNs while the indirect pathway is 
controlled by the enkephalin-D2-expressing MSNs (Groenewegen, 2003; Keeler, Pretsell, 
& Robbins, 2014). The repetitive behavior is believed to be due to an under-activity of 
the indirect pathway (Bechard, Cacodcar, King, & Lewis, 2016). 
 
1.3. Cells of the Basal Ganglia 
 The vast majority of the cell population in the striatum is the GABAergic 
medium-sized densely-spiny neurons (MSN) which receive excitatory corticostriatal 
inputs and serve as the projection neurons (Bolam et al., 2000). These neurons account 
for 90–95% of the striatal neurons, and they project to the globus pallidus or the 
substantia nigra pars reticulata (SNpr) (Bolam et al., 2000). 
 Another GABAergic neuronal population that resides in the striatum is the 
interneurons. Similarly, they receive excitatory input from the cortex, yet they exert some 
feed-forward inhibition on the medium spiny neurons rather than projecting to output 
nuclei. Their role is thought to be one of integrating the cortical information (Bolam et 
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al., 2000). Furthermore, these interneurons can be further identified based on their 
parvalbumin-expressing status as either parvalbumin-positive or parvalbumin-negative 
interneurons (Bolam et al., 2000). The interneurons that provide feed-forward inhibition 
are the parvalbumin-positive neurons (Bolam et al., 2000). 
 Thus, the anatomy of the basal ganglia is a heterogeneous one that contributes to 
its ability to be involved in multiple functional processes ranging from premotor and 
motor function to cognitive, emotional, and behavioral functions. Therefore, diseases 
falling under the umbrella of autism spectrum disorders (ASD) manifest as a disruption 
of those functions and may be related to an impairment in the basal ganglia. Hence, the 
basal ganglia may be implicated in autism and that is the question we raise here. 
 
1.4. Autism and the Basal Ganglia: 
 Autism is a pervasive developmental disorder characterized by repetitive 
stereotyped behaviors, social-emotional deficits, and delayed or absent language abilities 
(Blatt, 2012). The observed deficits are divided into at least three domains including 
social interactions, communication and language, and repetitive interests (Blatt, 2012). In 
the United States, 1 in 6 children had a developmental disability in 2006–2008. The 
prevalence of autism spectrum disorders was estimated to be 14.6 per 1000 children in 
2012 (Christensen et al., 2016). The total costs per year for children with ASD in the 
United States were estimated to be between $11.5 billion - $60.9 billion US dollars in 
2011 (Christensen et al., 2016). With such an economic burden, it is imperative to study 
the neurobiology of the disease in an effort for better understanding, prevention, and/ or 
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management. 
 The disease can be diagnosed according to the DSM-V and some of the key 
diagnostic symptoms are: (1) deficits in social-emotional reciprocity such as failure to 
initiate or respond to normal conversations; (2) deficits in the nonverbal communicative 
behaviors used for social interaction such as deficits in eye contact; (3) deficits in 
developing, maintaining, and understanding relationships such as difficulties in sharing 
play or in making friends (Blatt, 2012). However, the fifth edition (DSM-5) replaced 
these subcategories in favor of a unified autism spectrum disorder due to the low 
interrater agreement in clinical evaluations and unreliable characteristic features between 
subdivisions regarding the neuropathology or response to treatment (Chen, Peñagarikano, 
Belgard, Swarup, & Geschwind, 2015). So far, no distinctive ASD subtypes with typical 
pathological features have been specifically demonstrated (Chen et al., 2015).  
 Autism spectrum disorder involves autism disease, high- functioning Asperger’s 
disorder, and pervasive developmental disorder not otherwise specified (PDD-NOS) 
(Blatt, 2012).  Autism disorder diagnosis is made if certain symptoms are present by the 
age of 3 years, however, the age of 2 years is still acceptable for diagnosis. The 
diagnostic criteria include two or more symptoms in the social interaction domain, one 
symptom in the language and communication domain, and one symptom in the repetitive 
interest domain. Repetitive behavior is a broad term that refers to different patterns of 
behavior linked by repetition, inflexibility, invariance, and inappropriateness. Repetitive 
motor behaviors, also known as motor stereotypies, are considered manifestations of 
psychiatric, neurological, and developmental disorders, such as: obsessive compulsive 
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disorder, Tourette’s syndrome, Parkinson’s disease, and autism, (Bechard et al., 2016; 
Langen et al., 2011). However, these repetitive behaviors can also be expected in certain 
phases of typical development (Langen et al., 2011). Repetitive behaviors constitute the 
third domain in the diagnostic criteria of autism and their presence is essential for the 
diagnosis of the disorder (Blatt, 2012). The lack of symptoms in one of the domains other 
than the social domain excludes the diagnosis of autism disease (Blatt, 2012).  		
1.5. The GABAergic Hypothesis in Autism 
 Autism has a heterogeneous group of phenotypic manifestations, which renders 
identifying its underlying anatomical, genetic, neurobiological, and neurochemical 
mechanisms difficult.  Among the hypotheses suggested to be causative for the disease is 
the high excitation/ low inhibition of the cortex hypothesis (Rubenstein & Merzenich, 
2003). The imbalance between the cortical excitation and inhibition can be accounted for 
by an increase in glutamatergic activity or a decrease in the GABAergic activity 
(Rubenstein & Merzenich, 2003). 
 GABA, gamma-aminobutyric acid, is the most abundant inhibitory 
neurotransmitter in the adult human nervous system (Rubenstein & Merzenich, 2003). As 
such, mutations or environmental factors that decrease GABA signaling would increase 
the excitatory tone leading to epilepsy and cognitive dysfunction, which are, commonly 
associated co-morbidities with autism disease (Rubenstein & Merzenich, 2003). 
 In the cerebral cortex, roughly 80% of the neurons are excitatory glutamatergic 
neurons and 20% are inhibitory GABAergic neurons (Rubenstein & Merzenich, 2003). 
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Suppressed GABAergic inhibition is a commonly studied phenomenon in autistic 
individuals in various brain regions like the frontal cortex, the parietal cortex, and the 
cerebellum (Blatt & Fatemi, 2011). However, it was rarely studied in the basal ganglia 
(Harada et al., 2011; Rubenstein & Merzenich, 2003). Epilepsy is present in 25% of 
autism cases (Coghlan et al., 2012). Furthermore, epilepsy has been reported to be 
associated with GABAergic deficiency. Indeed, several studies showed that inhibiting 
GABA synthesis or antagonizing GABAA receptors stimulates the central nervous system 
and induces seizures (Fernandez et al., 2007; Horton & Meldrum, 1973). Hence, the basal 
ganglia are the vital source of cortical GABAergic neurons, the basal ganglia might be 
involved in the pathology leading to the hyper-excitable cortex (Ramamoorthi & Lin, 
2011; Rubenstein & Merzenich, 2003; Rubin et al., 2010). Defects in either the 
production or migration of basal ganglia GABAergic neurons lead to diminished numbers 
of cortical GABAergic neurons that result in a hyper-excitable cortex (Rubenstein & 
Merzenich, 2003). 
 The GABAergic system involvement in autism was evident in several postmortem 
human studies and in several brain regions. These studies found a decrease in the GABA- 
synthesizing enzymes GAD67 and GAD65, glutamic acid decarboxylases type-67 and 
type-65, respectively, in the parietal cortex and in the cerebellum of autistic brains 
(Fatemi et al., 2002). One neuropathological study of 8 autistic postmortem brains 
revealed that the Purkinje cells in the cerebellum showed a decrease in their expression of 
the GAD67 mRNA levels by 40% as compared to 8 matched controls (Yip et al., 2007). 
However, the same study showed elevated GAD67 mRNA levels in basket cells (Yip, 
 10 
Soghomonian, & Blatt, 2008). These findings suggest that not all GABAergic cells are 
affected similarly or equally in autism. However, abnormalities observed in the 
cerebellum are still fairly difficult to explain in terms of the clinical presentation and the 
symptoms of autism. Another study found a decrease by 60% in the GAD67 expression 
in the parietal cortex (Fatemi et al., 2002).  
 Although no similar histochemical studies were conducted in the basal ganglia 
region, some studies examined the neuroanatomical attributes to the symptoms of autism 
disorder. These neuroimaging studies provide ambivalent suggestions for anatomical 
defects, at least in some autistic individuals. A well-controlled study detected increased 
caudate volume in individuals with autism compared to matched healthy controls, and 
this increase was proportional to the increase in the total brain volume (Hollander et al., 
2005). In this study, 35 adolescents and adults with autism and 36 healthy controls were 
imaged by magnetic resonance imaging (MRI), and the volumes of all basal ganglia 
structures were measured. Individuals with autism had larger caudate volumes than 
healthy controls. The effect was not significant when the caudate volumes were corrected 
for total brain volume. This study suggests that there are basal ganglia abnormalities in 
the autistic brains that may correlate with some of the autistic symptoms such as the 
repetitive behavior. Moreover, repetitive behavior was studied and associated with 
morphometric changes of the caudate nucleus (Langen, Durston, Staal, Palmen, & 
Engeland, 2007). Nevertheless, the results pertaining to the correlation between the 
caudate volume and the repetitive behavior in autism were equivocal (Hollander et al., 
2005). 
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1.6. Parkinson’s Disease and the Dorsolateral Prefrontal Cortex 
 Parkinson's disease is the second most common neurodegenerative disorder and 
the most common movement disorder (Kikuchi et al., 2001). The depletion of the 
neurotransmitter dopamine due to the degeneration of the dopaminergic neurons in the 
substantia nigra is the hallmark of Parkinson’s disease (Dauer & Przedborski, 2003). 
Usually, Parkinson’s disease begins between the ages of 50 and 65, striking about 1% of 
the population in that age group. In 2013, PD was present in 53 million people and 
resulted in about 103,000 deaths globally (Naghavi et al., 2015). Dopamine depletion is 
associated with regulatory changes in its corresponding two receptors, commonly, D1 
receptor and D2 receptor (Gerfen et al., 1990). Dopamine receptor 1 gene (DRD1) is 
highly expressed in the deep layers of the cerebral cortex and the striatum (Jiang et al., 
2015). While DRD1 gene expression has been extensively studied in the basal ganglia in 
the literature, it was sparsely documented in the dorsolateral prefrontal cortex (DLPFC) 
(Hurley, Mash, & Jenner, 2001). The dorsolateral prefrontal cortex has been implicated in 
Parkinson’s disease. Patients with Parkinson's disease (PD) often suffer from 
impairments in executive functions and working memory deficits (Trujillo et al., 2015). 
Working memory and executive deficits are often present in the early stages of PD (Cools 
& Robbins 2004). Dubois and Pilon (1997) presented data indicating that about 93% of 
PD patients present with cognitive, mostly executive, deficits (Brozoski, Brown, 
Rosvold, & Goldman, 1979). Decreases in regional cerebral blood flow in the 
dorsolateral prefrontal cortex (DLPFC) in PD patients were shown to correlate with 
disease severity (Lanoue, Blatt, & Soghomonian, 2013). Unlike the striatum, where 
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dopamine receptors are predominantly expressed on GABAergic MSNs, cortical 
dopamine receptors are found on both excitatory (glutamatergic) and inhibitory 
(GABAergic) cell types. As a result, dopaminergic activity in the cerebral cortex has 
been shown to elicit both excitatory and inhibitory responses (Jiang et al., 2015). 
However, an ample amount of research has investigated D1 receptor expression in young 
and old subjects and showed that age is a major factor influencing the release of 
dopamine during cognitive tasks (Bäckman, Lindenberger, Li, & Nyberg, 2010). 
Moreover, some studies investigated the DRD1 expression in the DLPFC of 
schizophrenics and bipolar patients, but not in Parkinson’s disease (PD) patients. To our 
knowledge, the mRNA expression of the DRD1 gene has not been studied in dorsolateral 
prefrontal cortex (DLPFC) in patients with Parkinson’s disease in the postmortem human 
brain (Mattay et al., 2002). The current study explores the use of a newly emerging 
method to hybridize mRNA in situ, specifically the RNAscope HD2.0 Brown detection 
kit marketed by ACD (Advanced Cell Diagnostics). 
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Figure 1. Basal Ganglia Circuitry. 
Schematic representation of the basal ganglia connections. Corticostriatal glutamatergic 
excitatory (indicated in purple arrows) input flows to the caudate, putamen, and 
subthalamic nucleus. The GABAergic inhibitory medium spiny neurons (MSN) 
(indicated in blue arrows) of the striatum project to the pallidum (globus pallidus internus 
and globus pallidus externus), and the substantia nigra pars reticulata. The output 
projection neurons of the globus pallidus internus (GPi) inhibit the thalamo-cortical 
excitation in the direct pathway. The indirect pathway follows through the globus 
pallidus externus (GPe) that inhibits the subthalamic nucleus excitatory input to the GPi, 
and subsequently, disinhibiting the thalamo-cortical flow. The substantia nigra pars 
compacta dopaminergic neurons modulate the medium spiny neuronal activation 
(indicated in red arrows). 
Legend: D: dopaminergic innervation. GPi: globus pallidus internus. GPe: globus 
pallidus externus. Put.: putamen. STN: subthalamic nucleus. SNpc: substantia nigra pars 
compacta. SNpr: substantia nigra pars reticulata. 
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2. METHODS 
 
2.1. The Human Basal Ganglia Specimens for In Situ Hybridization 
For the in situ hybridization histochemistry, fifteen human basal ganglia 
specimens including 7 autism cases (5 male) and 8 control subjects (5 male) were 
obtained from the University of Maryland Brain and Tissue Bank (Brain and Tissue 
repository of the NIH NeuroBioBank). Information regarding the RNA integrity number 
(RIN), pH, age at death, and the postmortem interval (PMI) was provided in the tissue 
information sheet for all subjects except for five cases. The tissue blocks were stored at 
−80 °C. Using the Cryostat at −20 °C, the specimens were sliced coronally into 10µm-
thick sections, mounted on Chrom-Alum gelatin-coated 50x75 mm glass slides, and 
immediately stored in −80 °C freezer. A minimum of two adjacent sections per subject 
was used for the in situ hybridization to ensure the consistency of the results per subject. 
 
2.2. In Situ Hybridization 
2.2.1. The Preparation of Pre-hybridization and Post-hybridization Solutions  
 The pre-hybridization and the post-hybridization solutions were prepared using 
double distilled water (dd-H2O). The pre-hybridization solutions included: 0.1M PBS, 
3% paraformaldehyde fixative, 2xSSC, 0.1M Triethanolamine, 0.1M Tris-Glycine, 1M 
DTT, 70%, 80%, and 95% percent Ethanol/DEPC-H2O for washes. 
 The post-hybridization solutions were: 50% Formamide/2xSSC, RNAseA, 
2xSSC, 2xSSC/Triton, 300mM Ammonium acetate, 70% EtOH/DEPC-H2O, and 80% 
EtOH/DEPC-H2O. 
 15 
	
2.2.2. Fixation, Pre-hybridization and Hybridization of Tissue Sections 
 The slides were removed from the −80 °C freezer and thawed at room 
temperature using cool-air blow-dryer. Afterwards, slides were arranged inside a metal 
rack and fixed in 3% paraformaldehyde/0.1M PBS for 5 minutes on a shaker. After 
fixation, slides were washed with several solutions all on the shaker starting immediately 
with 0.1 MPBS for one minute, two 2xSSC washes one-minute each, 0.1 M TEA/ acetic 
anhydride for 10 minutes, 2xSSC for 1 minute, 0.1M PBS for another minute, 0.1M Tris-
Glycine for 30 minutes, two one-minute washes with 2xSSC, and finally, 70% 
EtOH/DEPC-H2O, 80% EtOH/DEPC-H2O, and 95% EtOH/DEPC-H2O washes and they 
were left for air-drying. 
 Before incubating the slides, each section was covered-fully with the proper 
amount of probe, the humidity chamber was set, and the tissue sections were cover-
slipped with parafilm, arranged evenly in the humidity tray and incubated in the 52 °C 
oven for 4 hours. 
 After incubation, the slides were placed inside the metal rack containing 2xSSC 
for 1 minute and the parafilm coverslip was removed. Next, the slides were submerged in 
50% Formamide/ 2xSSC while in the 52 °C water bath for 5 minutes followed by three 
one-minute washes in 2xSSC. After that, sections were incubated in RNAseA while in 
the 37 °C water bath for 30 minutes followed by another three one-minute 2xSSC 
washes. Again, slides were washed in 50% Formamide/ 2xSSC in 52 °C for 5 minutes 
while gently shaking and washed with another 2 one-minute 2xSSC washes on the 
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shaker. Finally, the slides rack was left overnight in 2xSSC/ 0.05Triton X shaking at 
room temperature. 
 The next day, all washes were done while on the shaker except for xylene. The 
slides had 2 quick rinses 2xSSC/ 0.05Triton X followed by a quick rinse in 300M 
Ammonium acetate, and then by, 70% EtOH/Ammonium acetate for 1 minute. Another 
two washes, each for one minute, were done in 80% EtOH/ Ammonium acetate and 95 % 
Ethanol, two five-minute washes in the 100% Ethanol, and xylene under the fume hood 
for 5 minutes, 30 minutes, and finally for the last 100% Ethanol for five minutes on the 
shaker. 
When slides dried, they were placed in an X-ray cassette. The cassettes were 
wrapped in aluminum foil and the films were left to expose for a period of 15 days. After 
the films developed, slides were processed for emulsion radioautography by dipping in 
Kodak NTB3 nuclear emulsion, air-dried for 3 hours, and stored in light-tight boxes for 
14 days. Sections were lightly counterstained with Eosin and Hematoxylin, and mounted 
with Eukitt (Sigma-Aldrich Chemicals, St. Louis, MO). 	
2.3. Human Dorsolateral Prefrontal Cortex Specimens for RNAscope 
 The RNAscope® is a new in situ hybridization technology developed and 
marketed by Advanced Cell Diagnostics (ACD). The RNAscope® Assay uses a novel 
method of in situ hybridization (ISH) to visualize single RNA molecules per cell in 
mounted sections without the use of radioactive probes. The RNAscope 2.0 Brown kit 
(Cat. No 310033 or 310035) was used to label the DRD1 mRNA in the dorsolateral 
prefrontal cortex of 3 Parkinson’s Disease and 6 control tissue sections and using the 
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manufacturer’s protocol for preparing and pretreating the fresh frozen tissue with 
minimal modification (http://acdbio.com/kits-reagents-manual-assays). 
  
2.3.1. The RNAscope Assay 
 The RNAscope 2.0 HD Assay includes 6 steps that require three kits. The six 
steps are: permeabilization, hybridization, amplification, visualization, and quantification. 
In the permeabilization step, the tissue sections are fixed for 5 minutes either in 10% 
Neutral Buffered Formalin (NBF) or 5% paraformaldehyde at 4 °C and pretreated with 
RNAscope® Pretreatment Kit to unmask target RNA and permeabilize cells.  
 Although the RNAscope Pretreatment 4 is recommended for fresh frozen tissue, 
in the current study, Pretreatment 1 and Pretreatment 3 generated better results. Both 
Pretreatment 3 and Pretreatment 4 are proteases while Pretreatment 1 is a peroxidase.  
Moreover, the pretreatment incubation times were modified accordingly in order to 
optimize our results based on the manufacturer’s recommendations.  
 
2.3.2. Sample Preparation and Pretreatment 
 Slides were removed from the −80 °C freezer and immediately immersed for 5 
minutes in 10% NBF at 4 °C. After fixation, slides were dehydrated in 50% Ethanol, 70% 
Ethanol, and 100% Ethanol at room temperature, respectively. Slides were then dried at 
room temperature and thick barriers were drawn around each section using the 
ImmEdge™ hydrophobic barrier pen. Next, 5 drops (150µl) of Pretreatment 1 were 
applied to tissue sections and slides were incubated at room temperature for 10 minutes. 
Afterwards, slides were stacked in the Tissue-Tek slide rack and washed twice in tissue 
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staining dishes filled with distilled water. In a similar way, 5 drops of Pretreatment 3 
were applied to slides and incubated at room temperature for 30 minutes before washing 
them twice in distilled water. 
 
2.3.3. Hybridizing Sections with DRD1 Probe 
 Five drops of the DRD1 probe were applied on each section. Sections were placed 
in a humidity plastic chamber layered with wet Whatman paper. The sections were 
incubated at 40 °C in a forced-air oven for 2 hours. After that, slides were removed from 
the oven and washed twice in 1xRNAscope Wash Buffer each for two minutes.  
	
2.3.4. Amplifications Steps 
 The six amplifiers are numbered to be used in the order Amp1, Amp2, Amp3, 
…etc. The first four were applied to sections and incubated according to their 
corresponding specified times. Amplifiers Amp1 and Amp3 were incubated for 30 
minutes at 40 °C while Amp2 and Amp4 were incubated for 15 minutes at 40 °C inside 
the forced-air oven. Amplifier 5 and amplifier 6 were applied and incubated at room 
temperature for 30 minutes and 15 minutes, respectively. Between each amplifier and the 
next one, sections were washed twice in the 1xRNAscope Wash Buffer for two minutes 
under gentle agitation. 	
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2.3.5. Signal Detection 
 I mixed appropriate amounts of DAB A and DAB B (150 µl/slide = 75 µl DAB A 
+ 75µl DAB B) to cover each section and sections were incubated at room temperature 
for 10 minutes after which DAB was disposed in bleach while slides were washed twice 
in double-distilled water (dd-H2O). 
 
2.3.6. Counterstaining, Dehydration, and Mounting 
 Slides were stained by submerging them in 50% Hematoxylin for 2 minutes at 
room temperature, two distilled water washes, and a brief immersion in 0.02% Ammonia 
water with a last dd-H2O wash. 
 Following the counterstaining, the slides were dehydrated in 70% EtOH, and two 
100% EtOH for two minutes each followed by xylene for five minutes. In the fume hood, 
24×50 mm coverslips were applied to the slide using Cytoseal mounting medium. 
 
2.3.7. Visualization 
 Slides were kept overnight to ensure complete drying and they were visualized the 
next day under bright-field microscope, 60X magnification. 
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2.4. Quantification and Data Analysis 
2.4.1. Quantification of GAD67 mRNA-labeled Caudate and Putamen Emulsion 
Radioautograph Sections on Single Cell Level 
 
 After processing a total of 30 slides using the in situ hybridization histochemistry 
and emulsion autoradiography, the 16 control and 14 autistic basal ganglia slides were 
analyzed under bright-field illumination with a 60X objective magnification using a 
Nikon E600 microscope connected to a Sony CCD camera, which was connected to a 
Macintosh computer. The tissue section images were captured live and analyzed using 
the software Scion NIH Image 1.61 under constant microscopic illumination and contrast 
settings of the software. 
 In each section, neurons with overlying silver grains were selected using a fixed 
outline, and density slice function was used to measure pixels per unit area. Density of 
GAD67 mRNA-labelled cells was measured in a total of forty cells per section (See 
Figure 2.  Photomicrograph of labeled neuron). In addition, other numeric data pertaining 
to the autism group and the control group were summarized and an independent t-test was 
carried out in GraphPad Prism 6. 
2.4.2. Quantification of GAD67 mRNA-labeled Caudate and Putamen on X-ray Films 
Radioautographs 
 The analog signals of the GAD 67 mRNA-labeled X-ray films were digitalized 
and analyzed using a Macintosh computer connected to a Sony CCD video camera. The 
GAD 67 mRNA-labeled X-ray films were converted to a digital image of 640 × 480 
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pixels using NIH ImageJ64 Software (http://imagej.nih.gov/ij/download.html). The 
freehand tool was used to delineate the striatal area to be measured in each section. The 
area inside the outline was measured in pixels. Two adjacent sections of each subject 
were quantified and the mean of these two measurements was reported. In addition, 
GAD65 mRNA labeled images pertaining to the same subjects were quantified in a 
similar manner and analyzed along with the GAD67 mRNA labeled X-ray images. 
 
2.4.3. Data Retrieval and Scoring Guidelines for the DRD1 mRNA-labeled 
Dorsolateral Prefrontal Cortex Sections 
 The RNAscope® Assay uses a semi quantitative scoring approach that utilizes the 
estimated number of punctate dots present within each cell boundary (“Semi-quantitative 
and quantitative analysis,” n.d.). The RNAscope staining intensity for a gene with 
expression levels varying between 1–>10 copies per cell categorizes the staining into five 
grades; 0 score indicates no staining or < 1 dot to every 10 cells (40X magnification), 1+ 
score for 1–3 dots/cell, 2+ score for 4–10 dots per cell, 3+ score for >10 dots per cell in 
less than 10%, and 4+ score for >10 dots per cell in more than 10%. However, in our 
quantification of the RNAscope sections we used a quantitative approach. In each 
section, 50 neurons were quantified, and the number of the dots per neuron was reported. 
So, at least 100 neurons were counted per subject and the number of average number of 
dots per subject was used for the statistical analyses. 
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2.4.4. Statistical Analysis 
 The p-value<0.05 was considered significant, unless specified otherwise. For the 
in situ hybridization studies, comparisons between the autism group and the control 
group regarding GAD67 mRNA labeling levels on the X-ray films and on the emulsion 
radioautographs were analyzed with two-tailed unpaired t-tests. Furthermore, GAD65 
mRNA-labeled X-ray films were analyzed for examining the correlation between 
correlation between the GAD67 and GAD65 mRNA levels on the X-ray films. In 
addition, correlations between GAD67 mRNA labeling on the X-ray films and age at 
death, PMI, and pH were analyzed using linear regression.  
 For the RNAscope in situ hybridization, the Parkinson’s group and the control 
group were compared using independent t-test. However, due to the lack of the subject 
information sheets, further correlations could not be established.  
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3. RESULTS 
3.1. GAD67 mRNA-labeled X-ray Films and Emulsion Radioautographs 
 The GAD67 mRNA labeling that was measured and the t-test showed that the 
autism and the control group did not reveal a significant difference in their 
GAD67mRNA labeling neither on the X-ray films nor on the emulsion radioautographs. 
The quantitative analysis of the GAD67 mRNA labeling on X-ray films in the striatum of 
the autistic individuals (n= 6) and the control subjects (n= 8) was not significantly 
different (mean±SEM respectively 0.06279 ± 0.003535, and 0.06565 ± 0.003445; p= 
0.5806). 
 The quantitative analysis of emulsion radioautograph was consistent with this 
finding as the t-test did not show a significant difference between the groups: t= 0.2732 
df= 12; p= 0.7893. 
 While the mean GAD67 mRNA labeling intensity measured in pixels per neuron 
for the autism group was 110.4 ± 18.14 pixels, n= 6, the mean of the control group was 
104.3 ± 13.84 pixels, n= 8. The independent t-test value was t= 0.2732; df= 12; p-value= 
0.7893 (p-value<0.05, two-tailed, insignificant), shown on (Figure 3). GAD65 mRNA 
analyses showed no difference between the two groups.  
 Frequency distribution of neuronal profiles in the autism group and the control 
group showed similar patterns along with insignificantly different levels of median; 
autism group median= 92, control group median= 95), (Figure 4). 
 Multiple correlation and regression analyses were also performed. The linear 
regression analyses detected a significant relationship between the GAD67 mRNA 
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labeling on X-ray films and the age at death in the autism group (r= −0.862, p= 0.027), 
but not in the control group, (Figure 5). The regression analysis was insignificant 
between the RIN of the cortex and the GAD67 mRNA labeling of the striatum in all of 
the ten measured cases as five of the subjects were excluded from the analysis due to the 
insufficiency of the data provided. Pearson’s correlation coefficient and linear regression 
analyses were used to illustrate the relationship between the GAD67 mRNA levels on the 
X-ray films and the pH, the RIN of the cortex, and the RIN of the cerebellum. However, 
none of these technical measures reached statistical significance in both groups as shown 
in (Figure 6). 
  
3.2. DRD1 mRNA-labeling in the Dorsolateral Prefrontal Cortex Using RNAscope 
 The quantitative analysis of the number of chromogenic dots indicating DRD1 
mRNA labeling in Parkinson’s cases and controls revealed a significant difference in the 
average counted staining. The average number of chromogenic dots in the three 
Parkinson’s cases was as follows, the mean±SEM= 3.493 ± 0.2136, n= 3; while the 
control group mean± SEM= 2.815 ± 0.1128, n= 6. Unpaired t-test yielded t= 3.134; df= 
7, two-tailed p-value= 0.0165 (p<0.05, significant) (Figure 7 and Figure 8).  
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Figure 2. Photomicrograph of GAD67 mRNA-labeled neuron. 
Bright-field photomicrograph illustrating silver grains overlying a neuron on emulsion 
radioautographs of the striatum (E600 Nikon, 60X). 
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Figure 3. Levels of GAD67 mRNA labeling in the striatum emulsion radioautograph 
sections in autism and control groups. 
Independent t-test showed no significant difference in the mean number of pixels per 
neuron between the autism group (n= 6) and the control group (n= 8). Values represent 
the mean (±SEM) mRNA labeling measured in pixels from emulsion radioautographs. 
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Figure 4. Histograms of frequency distribution of GAD67 mRNA labeling in the 
striatum of control group (A) and the autism group (B). GAD67 mRNA labeling was 
expressed as number of pixels. 
In control cases (A), the median number of pixels per neuron is 95 and the mean is 106.8 
pixels. In autism cases (B), the median number of pixels per neuron is 92 and the mean is 
107.8 pixels per neuron. 
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Figure 5. Linear regression between the GAD67 mRNA labeling intensity on the X-
ray films and the age at death.  
The linear regression in autism group (A) showed a significant negative correlation (r= 
−0.8625; p= 0.027, significant) whereas in the control group (B) the relation was 
insignificant. 
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Figure 6. Linear regression analyses between GAD67 mRNA and pH, RINcx, RINcb 
in autism group and control group.  
Mean number of pixels representing GAD67 mRNA labeling measured on X-ray films. 
There was no significant correlation between GAD67 mRNA labeling and the pH in (A) 
autism group and (B) control group (Pearson correlation coefficient for autism group and 
control group, respectively: (r= 0.16; and r= 0.19), RINcx in (C) autism group and (D) 
the control group: (autism group, r= 0.09; and control group, r= 0.11), RINcb in (E) 
autism group and (F) control group: (autism group, r= 0.07; and control group, r= 0.35).  
Legend: RINcx: RNA integrity number of the cortex; RINcb: RNA integrity number of 
the cerebellum. 
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Figure 7. Levels of chromogenic DRD1 mRNA in PD and control groups.  
Mean number of the chromogenic dots representing DRD1 mRNA labeling in the 
Parkinson’s disease group and the control group differed significantly (t= 3.13, p= 
0.0165, significant). 
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Figure 8. Photomicrographs of RNAscope DRD1 mRNA labeling in a neuron. 
RNAscope Brown chromogen dots represent mRNA copies in DRD1 RNAm-labeled 
neuron in: (A) PD and (B) controls (E600 Nikon, 60X). 
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4. DISCUSSION 
4.1. GAD67 mRNA-labeled Striatal Sections  
 The in situ hybridization emulsion radioautographs results indicate that there is no 
significant difference in the expression of GAD67 mRNA levels in the postmortem 
human caudate/ putamen sections of autism cases and non-autistic control sections. 
Furthermore, GAD67 mRNA levels showed no correlation with the RIN of the cortex, 
RIN of the cerebellum, and the pH of the ten subjects studied. 
 Autism spectrum disorder (ASD) comprises a group of developmental disabilities 
characterized by impaired social interaction and communication accompanied by 
stereotyped behaviors and restricted interests (Chen et al., 2015). The disease has a broad 
continuum of clinical phenotypes. However, the underlying neurobiological mechanisms 
and the involved brain regions are yet to be identified. Among the commonly suggested 
neurobiological mechanisms is the disruption of the GABAergic system. Specifically, 
glutamic acid decarboxylase, GAD67 and GAD65, the key GABA-synthesizing enzyme 
isoforms (Gwak, Kang, Leem, & Hulsebosch, 2007). Although GABA activity in 
general, and GAD67 in particular, were investigated in some brain regions of autistic 
individuals, they were rarely studied in the postmortem autistic basal ganglia. After an 
extensive literature review, few studies were found to address similar questions to our 
study question yet the results in general are equivocal. 
 In one study, GABA activity was measured using proton magnetic resonance 
spectroscopy, [1H] MRS, in ASD volunteers. This study reported that GABA 
concentration was reduced in the frontal cortex of the children but no differences were 
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seen in the basal ganglia, specifically, in the putamen and globus pallidus (Coghlan et al., 
2012; Harada, Taki, & Naa, 2011). Furthermore, the cerebellum is among the well-
documented impaired regions of the brain in autism despite the fact that its clinical 
significance is unresolved. A study demonstrated a 40% reduction in GAD67 mRNA in 
Purkinje cells (PCs) in eight adult autistic cases compared to eight controls (Fatemi, 
2011). 
 A morphometric observation was made by Kanner’s original 1943 study 
identified that 5 of the 11 children had enlarged heads, a finding that has been 
consistently associated with ASD (Courchesne, Carper, & Akshoomoff, 2003). 
Macrocephaly associated with ASD can be explained by accelerated postnatal brain 
growth (Chen et al., 2015). Moreover, several MRI studies corroborated the increased 
total brain volume in autistic children. However, this increase was not explained or 
further investigated in terms of cellular and molecular pathology due to the technical 
difficulties concerning this type of studies in the living human subjects. In addition, the 
basal ganglia volume was measured repeatedly. Nevertheless, the MRI studies which 
focused on the basal ganglia of autistic brains revealed equivocal results. For instance, 
some of the results showed a decrease while others showed an increase in the volume of 
the basal ganglia, particularly, the caudate nucleus (Hollander et al., 2005; Langen et al., 
2007). 
 Thus, more well-controlled studies are required to confirm these findings and to 
investigate the mechanisms involved in the change in caudate volume and the identity of 
the overgrowing cellular population that may have contributed to this enlargement. 
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 The lack of correlation between GAD67 mRNA levels and the technical measures 
PMI and RNA Integrity Number (RIN) results were also documented in other genetic 
studies (Chen et al., 2015). The first relatively large study of idiopathic ASD 
transcriptomics profiled gene expression in three regions: superior temporal gyrus, 
prefrontal cortex, and cerebellar vermis in 19 ASD patients and 17 controls. This study 
found co-expressed modules of genes that were correlated with the presence or absence 
of ASD and two of these modules were uncorrelated with technical variables such as 
postmortem interval and RNA integrity number (Chen et al., 2015). However, Rabionet 
et al. reported a lack of evidence for association between the SNPs located in GAD1 gene 
and suggested that the results observed by Fatemi et al.  showing differences in GAD67 
levels in autistic brain samples compared to controls are probably not due to common 
mutations or variants in GAD1 gene (Rabionet et al., 2004). 
 Postmortem and structural magnetic resonance imaging studies have highlighted 
the frontal lobes, amygdala, and cerebellum as pathological in autism (Amaral, 
Schumann, & Nordahl, 2008). However, there is no clear and consistent pathology that 
has emerged for autism (Amaral et al., 2008). Postmortem techniques provide a tool for 
understanding the underlying neurobiology of observed neuroanatomical abnormalities. 
For instance, if the brain is larger, is the enlargement caused by an increase in neurons, 
fibers, axons, glia or synapses? (Amaral et al., 2008). The use of postmortem techniques 
as a tool for studying the neuroanatomy of autism is still very much in its infancy 
(Amaral et al., 2008). 
 Currently, one of the most prominent theories of the neuropathology of autism is 
that in autistic individuals the brain undergoes a period of precocious growth during early 
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postnatal life followed by a deceleration in age-related growth (Wegiel et al., 2014). The 
evidence for this early overgrowth comes from the observations that provide evidence for 
normal or smaller head circumference at birth followed by an increase in the rate of 
growth beginning at 12 months of age (Amaral et al., 2008). 
 
4.2. DRD1 mRNA Levels in the Dorsolateral Prefrontal Cortex 
 The dopamine 1 receptor DRD1 mRNA labeling in the dorsolateral prefrontal 
cortex showed significant increase in the Parkinson’s group in comparison to the control 
group on postmortem sections. This difference might have some implications regarding 
executive functions in the Parkinson’s group. It is well known in the literature that the 
dopamine alterations in the cortex affect working memory. A finding that is consistently 
seen in Parkinson’s disease (Backman et al., 2011). Data in rodents and non-human 
primates have shown that excessive or suboptimal stimulation of D1 receptors may result 
in working memory deficits (Abi-Dargham et al., 2011). The study conducted by Abi-
Dargham (2011) investigated the D1 receptor effect on the working memory of 
schizophrenic patients. The positron emission tomography and the D1 receptor tracer, 
[11C]NNC112, were used to determine the availability of D1 receptor in 12 drug- naïve 
and 13 drug free schizophrenic patients compared to 16 healthy controls. The binding 
potential was higher in the schizophrenic group. D1 receptor availability was measured in 
the dorsolateral prefrontal cortex and the striatum. The results showed a significant 
increase in the partial volume corrected binding potential in the drug naïve group but not 
in the drug free group as compared to the healthy controls. The study attributes these 
finding to an upregulation of the D1 receptor resulting from a dopamine-depleted state in 
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the DLPFC of schizophrenic patients (Brisch et al., 2014). The study explained the 
working memory deficits associated with schizophrenia as resulting from hypo-
stimulation of the DRD1 receptor (Abi-Dargham et al., 2011). In another 
methodologically similar study by the same researchers they found that the increase in 
the availability of the D1 receptor indicated by [11C]NNC 112 binding potential (BP) 
was associated with a poorer performance on the n-back task, a test of working memory, 
in 16 schizophrenic patients compared to 16 controls (Abi-Dargham et al., 2002). These 
explanations may provide insight to the increase in the DRD1 receptor mRNA labeling in 
the Parkinson’s group as it may be related to compensatory upregulation in response to 
chronic deficits in dopamine tone (Abi-Dargham et al., 2011). However, the lack of 
records on the treatment-status of the subjects makes this relation difficult to assert in our 
study. Moreover, one study found that the D1 receptor downregulation was observed in 
the drug naïve schizophrenic individuals according to a PET scan study (Okubo et al., 
1997). Another study by Cools et al. examined the effect of the L-dopa treatment on the 
cognition of 11 PD patients by scanning them while doing the Tower of London task and 
a spatial memory task in two occasions: the first setting is when they were Off-L-dopa 
treatment, and in the second setting, they were on-L-dopa. The patients showed an 
improved performance on both tasks when they were on-L-dopa (Cools et al., 2002). 
However, other studies suggest that chronic treatment with L-dopa might improve the 
motor function in Parkinson’s disease, yet worsen some of the cognitive functions 
(Jahanshahi et al., 2010). However, there is scarcity of knowledge about the capacity of 
L-dopa and dopamine receptor agonists in improving the cognitive deficits in PD 
(Nieoullon, 2002). 
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 Unlike the striatum, where dopamine receptors are predominantly expressed on 
GABAergic MSNs, cortical dopamine receptors are found on both excitatory 
(glutamatergic) and inhibitory (GABAergic) cell types (Jiang et al., 2015). Thus, the 
dopaminergic activity in the cortex can induce both inhibitory and excitatory responses. 
Some studies have shown that the D1 receptor changes, both an increase and a decrease, 
are implicated in functions like learning and memory (Castner et al., 2000). A study 
evaluated the mRNA and the protein level of the DRD1 in Parkinsonian patients 
demonstrated an increase in the striatum and a decrease in the expression in extrastriatal 
areas (Hurley et al., 2001). Therefore, some studies concerning the DRD1 receptor 
density in the dorsolateral prefrontal cortex disprove the view that DRD1 receptors 
expression should follow striatal patterns in Parkinson’s disease. The prefrontal cortex is 
a primary site of projection for ventral tegmental area dopaminergic neurons. The 
dopaminergic neuronal degeneration is less observed in the ventral tegmental area as 
compared to the SNpc in Parkinson’s Disease (Dauer & Przedborski, 2003), and hence, 
the DRD1 receptors in the prefrontal cortex might not suffer dopamine depletion as the 
DRD1 striatal counterparts (Dauer & Przedborski, 2003). Our observed increase in the 
DRD1 mRNA labeling in the DLPFC of PD patients can be explained in parallel to the 
increase observed in the striatum of Parkinson’s patients. Therefore, more histochemical 
studies are required to ascertain the genetic expression involving the D1 receptor in a 
timely pattern as Parkinson’s disease progresses. Genetic profile mapping research would 
be an essential first step in establishing a standard reference for comparing the DRD1 
gene expression between Parkinson’s patients and the normal population. 
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